San Carlos, United States
Onc.AI, founded in 2020, is making significant strides in the Biotechnology and Health Care industries. This United States-based company provides non-invasive radiomic-based biomarkers designed to support clinical decision-making.
True to their slogan, "Non-invasive radiomic-based biomarkers for clinical decision support," Onc.AI focuses on optimizing immunotherapy through their advanced imaging-AI powered platform. Their innovation hinges on patented AI models that utilize routine diagnostic imaging scans, particularly for recommending and guiding first-line immune checkpoint inhibitors (ICI) treatment plans.
Backed by a robust Series A investment of $25.00M secured on 05 January 2023, Onc.AI has garnered support from top-tier investors such as KdT Ventures, Accomplice, Digitalis Ventures, Life Extension Ventures, MassMutual, Action Potential Venture Capital, and The Blue Venture Fund. This financial endorsement underscores the industry's confidence in Onc.AI's innovative solutions and its potential to transform clinical oncology management.
